Literature DB >> 21610512

Effect of the plasminogen-plasmin system on hypertensive renal and cardiac damage.

Benjamin Knier1, Nada Cordasic, Bernd Klanke, Juliane Heusinger-Ribeiro, Christoph Daniel, Roland Veelken, Andrea Hartner, Karl F Hilgers.   

Abstract

BACKGROUND: The plasminogen-plasmin system affects tissue fibrosis, presumably by interacting with metalloproteinases (MMPs) and macrophage recruitment. This study tests the influence of plasminogen activator inhibitor-1 (PAI-1) and tissue-type plasminogen activator (tPa) on angiotensin II-mediated hypertensive kidney and heart injury.
METHOD: Hypertension was induced by continuous angiotensin II (Ang II) infusion via osmotic mini-pumps over 4 weeks. The effects of Ang II infusion were determined in mice lacking PAI-1 (PAI-1), mice lacking tPa (tPa), and wild-type mice. Normotensive mice of the respective genotype served as controls. Blood pressure was recorded by continuous radiotelemetric intra-arterial measurements.
RESULTS: Ang II infusion significantly enhanced arterial blood pressure in all groups. However, the increase in blood pressure was more pronounced in the tPa group. Albuminuria was highest in hypertensive wild-type compared to the other Ang II-infused groups. Hypertensive PAI-1 mice exhibited less glomerulosclerosis, higher nephrin immunostaining, and lower renal interstitial collagen I deposition. Gelatin zymography revealed higher activity of MMP-2 in hypertensive PAI-1, whereas no differences were observed in macrophage infiltration. tPa deficiency did not alter kidney fibrosis, although hypertensive tPa revealed less renal expression of fibrotic genes, less macrophage infiltration, and reduced MMP-2 activity. On the other hand, hypertension-induced fibrosis as well as macrophage infiltration in the heart was profoundly enhanced in PAI-1 mice. Fibrin staining revealed perivascular exudations in the myocardium of hypertensive PAI-1 suggesting vascular leakage.
CONCLUSION: These findings underscore the unexpectedly complex role of plasminogen activation for hypertensive target organ damage.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21610512     DOI: 10.1097/HJH.0b013e32834840e8

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  10 in total

1.  Plasminogen activator inhibitor 1, fibroblast apoptosis resistance, and aging-related susceptibility to lung fibrosis.

Authors:  Wen-Tan Huang; Hasina Akhter; Chunsun Jiang; Mark MacEwen; Qiang Ding; Veena Antony; Victor John Thannickal; Rui-Ming Liu
Journal:  Exp Gerontol       Date:  2014-11-28       Impact factor: 4.032

Review 2.  Zymography methods for visualizing hydrolytic enzymes.

Authors:  Jennifer Vandooren; Nathalie Geurts; Erik Martens; Philippe E Van den Steen; Ghislain Opdenakker
Journal:  Nat Methods       Date:  2013-03       Impact factor: 28.547

3.  A plasminogen activator inhibitor type 1 mutant retards diabetic nephropathy in db/db mice by protecting podocytes.

Authors:  Jiandong Zhang; Chunyan Gu; Daniel A Lawrence; Alfred K Cheung; Yufeng Huang
Journal:  Exp Physiol       Date:  2014-01-17       Impact factor: 2.969

4.  Immune responsive resolvin D1 programs myocardial infarction-induced cardiorenal syndrome in heart failure.

Authors:  Ganesh V Halade; Vasundhara Kain; Charles N Serhan
Journal:  FASEB J       Date:  2018-02-13       Impact factor: 5.191

Review 5.  Darkness at the end of the tunnel: poststenotic kidney injury.

Authors:  Alfonso Eirin; Lilach O Lerman
Journal:  Physiology (Bethesda)       Date:  2013-07

6.  Plasminogen Activator Inhibitor-1 Protects Mice Against Cardiac Fibrosis by Inhibiting Urokinase-type Plasminogen Activator-mediated Plasminogen Activation.

Authors:  Kamlesh K Gupta; Deborah L Donahue; Mayra J Sandoval-Cooper; Francis J Castellino; Victoria A Ploplis
Journal:  Sci Rep       Date:  2017-03-23       Impact factor: 4.379

7.  Anti-Apoptosis and Anti-Fibrosis Effects of Eriobotrya Japonica in Spontaneously Hypertensive Rat Hearts.

Authors:  Jui-Ting Chiang; Khan Farheen Badrealam; Marthandam Asokan Shibu; Sue-Fei Cheng; Chia-Yao Shen; Chih-Feng Chang; Yueh-Min Lin; Vijaya Padma Viswanadha; Shih-Chieh Liao; Chih-Yang Huang
Journal:  Int J Mol Sci       Date:  2018-05-31       Impact factor: 5.923

8.  Plasminogen activator inhibitor-1 reduces cardiac fibrosis and promotes M2 macrophage polarization in inflammatory cardiomyopathy.

Authors:  Christian Baumeier; Felicitas Escher; Ganna Aleshcheva; Heiko Pietsch; Heinz-Peter Schultheiss
Journal:  Basic Res Cardiol       Date:  2021-01-11       Impact factor: 17.165

9.  Irreversible renal damage after transient renin-angiotensin system stimulation: involvement of an AT1-receptor mediated immune response.

Authors:  Bart F J Heijnen; Jelly Nelissen; Helma van Essen; Gregorio E Fazzi; Jan W Cohen Tervaert; Carine J Peutz-Kootstra; John J Mullins; Casper G Schalkwijk; Ben J A Janssen; Harry A J Struijker-Boudier
Journal:  PLoS One       Date:  2013-02-28       Impact factor: 3.240

10.  Plasminogen Deficiency and Amiloride Mitigate Angiotensin II-Induced Hypertension in Type 1 Diabetic Mice Suggesting Effects Through the Epithelial Sodium Channel.

Authors:  Henrik Andersen; Maria Høj Hansen; Kristian B Buhl; Mette Stæhr; Ulla G Friis; Camilla Enggaard; Shanya Supramaniyam; Ida K Lund; Per Svenningsen; Pernille B L Hansen; Boye L Jensen
Journal:  J Am Heart Assoc       Date:  2020-11-20       Impact factor: 5.501

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.